Acticoat Absorbent and BCT Antimicrobial for STSG Donor Site on Thigh

Acticoat Absorbent and BCT Antimicrobial for STSG Donor Site on Thigh---A Randomised Controlled Trial

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01769144

Enrollment

Registered

2013-01-16

Start date

2013-01-31

Completion date

2014-04-30

Last updated

2013-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cicatrix, Pain, Pruritus, Wound Healing, Wound Infection

Keywords

wound healing, wound infection, pain, pruritus, cicatrix, dressings, acticoat absorbent, BCT, KoCarbonAg

Brief summary

This study aims to compare the effectiveness of two wound dressings, Acticoat Absorbent (AA) and BCT Antimicrobial (BCT) on Split Thickness Skin Graft (STSG) donor site.

Detailed description

Seventy patients who undergo STSG procedure in Kaohsiung Veterans General Hospital will be recruited. Two donor sites of equal lengths and widths on the same thigh, which are at least 2 cm apart will be covered randomly with AA and BCT each. Wound healing rate and infection rate will be assessed at 7 and 14 days after surgery. Degrees of pain and itchiness will be assessed daily with Visual Analogue Scale for the first 7 post-operative days. Scar appearance will be assessed with Vancouver Scar Scale 1, 3 and 6 months post-operatively.

Interventions

DEVICEActicoat Absorbent

wound dressing

DEVICEBCT

wound dressing

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* patients who need STSG, longer than 8 cm and wider than 5 cm, from their thighs

Exclusion criteria

* systemic steroid * old scar on thigh * systemic infection * anticipated use of antibiotics for more than 24 hours after operation * pregnancy * previous chemotherapy within 3 months before operation * anticipated chemotherapy within 3 months after operation * not over 20 years old * non-communicable * burn area more than 20% total body surface area * systemic auto-immune disease * liver cirrhosis * allergy to carbon fiber or alginate * anticipated MRI study * dry wound

Design outcomes

Primary

Measure	Time frame	Description
wound healing rate	7 days	percentage of wound area that has healed at this time
wound infection rate	7 days	—

Secondary

Measure	Time frame
scar appearance	1 month
pain and itchiness	1day

Countries

Taiwan

Contacts

Primary ContactKuei-Chang Hsu, MD

kchsu@vghks.gov.tw+886-7-3422121

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026